» Articles » PMID: 35565475

Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network

Abstract

The surgical specificities of advanced low-grade serous ovarian carcinoma (LGSOC) have been little investigated. Our objective was to describe surgical procedures/complications in primary (PDS) compared to interval debulking surgery (neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) and to assess the survival (progression-free (PFS) and overall survival (OS)) in patients with advanced LGSOC. We retrospectively analyzed advanced LGSOC from a nationwide registry (January 2000 to July 2017). A total of 127 patients were included (48% PDS and 35% NACT-IDS). Peritoneal carcinomatosis was more severe ( = 0.01 to 0.0001, according to sites), surgery more complex ( = 0.03) and late postoperative morbidity more frequent ( = 0.03) and more severe in the NACT-IDS group. PFS and OS were similar in patients with CC0 and CC1 residual disease after PDS or IDS. Prognosis was poorest for NACT-IDS patients with CC2/CC3 resection (PFS: HR = 2.31, IC95% (1.3-4.58); = 0.005; OS: HR = 4.98, IC95% (1.59-15.61); = 0.006). NACT has no benefit in terms of surgical outputs in patients with advanced LGSOC. Patients with complete resection or minimal residual disease (CC0 and CC1) have similar prognoses. On the other hand, patients with CC2 and more residual disease have similar survival rates compared to nonoperated patients. Primary cytoreduction with complete or with minimal residuals should be preferred when feasible.

Citing Articles

Fluorescence-Guided Surgery to Detect Microscopic Disease in Ovarian Cancer: A Systematic Review with Meta-Analysis.

Erdemoglu E, Langstraat C, Kumar A, Ostby S, Girardo M, Giannini A Cancers (Basel). 2025; 17(3).

PMID: 39941778 PMC: 11815761. DOI: 10.3390/cancers17030410.


Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?.

Onoprienko A, Bartl T, Grimm C, Concin N, Polterauer S Cancers (Basel). 2024; 16(19).

PMID: 39409889 PMC: 11476324. DOI: 10.3390/cancers16193268.


Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.

Matsuo K, Matsuzaki S, Maeda M, Rau A, Yoshihara K, Tamura R JAMA Netw Open. 2023; 6(6):e2318602.

PMID: 37326992 PMC: 10276312. DOI: 10.1001/jamanetworkopen.2023.18602.


Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.

De Decker K, Wenzel H, Bart J, van der Aa M, Kruitwagen R, Nijman H Acta Obstet Gynecol Scand. 2023; 102(3):246-256.

PMID: 36734363 PMC: 9951382. DOI: 10.1111/aogs.14518.

References
1.
Malpica A, Deavers M, Lu K, Bodurka D, Atkinson E, Gershenson D . Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4):496-504. DOI: 10.1097/00000478-200404000-00009. View

2.
Aletti G, Dowdy S, Podratz K, Cliby W . Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007; 197(6):676.e1-7. DOI: 10.1016/j.ajog.2007.10.495. View

3.
Romero I, Sun C, Wong K, Bast Jr R, Gershenson D . Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol. 2013; 130(3):660-6. DOI: 10.1016/j.ygyno.2013.05.021. View

4.
Kurman R, Shih I . The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34(3):433-43. PMC: 2841791. DOI: 10.1097/PAS.0b013e3181cf3d79. View

5.
Gershenson D, Sun C, Lu K, Coleman R, Sood A, Malpica A . Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006; 108(2):361-8. DOI: 10.1097/01.AOG.0000227787.24587.d1. View